{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:34:37Z","timestamp":1747204477878,"version":"3.40.5"},"posted":{"date-parts":[[2023,2,22]]},"group-title":"In Review","reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,9]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background:<\/bold> Despite the development of several FLT3 inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemias (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways such as those regulated by BTK, aurora kinases, and potentially others in addition to acquired tyrosine kinase domains (TKD) mutations of<italic> FLT3<\/italic> gene. <italic>FLT3<\/italic>may not always be a driver mutation.\n<bold>Objective:<\/bold> To evaluate the anti-leukemia efficacy of the novel multi-kinase inhibitor CG-806, which targets FLT3 and other kinases, in order to circumvent drug resistance and target <italic>FLT3<\/italic> wild-type (WT) cells.\n<bold>Methods<\/bold>: The anti-leukemia activity of CG-806 was investigated by measuring apoptosis induction and analyzing cell cycle with flow cytometry <italic>in vitro<\/italic>, and its anti-leukemia\n<bold>Results:<\/bold> CG-806 demonstrated superior anti-leukemia efficacy compared to commercially available FLT3 inhibitors, both <italic>in vitro<\/italic> and <italic>in vivo<\/italic>, regardless of <italic>FLT3<\/italic> mutational status. The mechanism of action of CG-806 may involve its broad inhibitory profile of FLT3, BTK, and aurora kinases. In<italic>FLT3<\/italic> mutant cells, CG-806 induced G1 phase blockage, while in <italic>FLT3<\/italic>WT cells, it resulted in G2\/M arrest. Targeting FLT3 and Bcl-2 and\/or Mcl-1 simultaneously resulted in a synergistic pro-apoptotic effect in <italic>FLT3<\/italic>mutant leukemia cells.\n<bold>Conclusion:<\/bold> The results of this study suggest that CG-806 is a promising multi-kinase inhibitor with anti-leukemia efficacy, regardless of <italic>FLT3<\/italic> mutational status. A phase 1 clinical trial of CG-806 for the treatment of AML has been initiated (NCT04477291).<\/p>","DOI":"10.21203\/rs.3.rs-2570204\/v1","type":"posted-content","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T23:30:18Z","timestamp":1677108618000},"source":"Crossref","is-referenced-by-count":1,"title":["The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases"],"prefix":"10.21203","author":[{"given":"Guopan","family":"Yu","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-6322","authenticated-orcid":false,"given":"Weiguo","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Aptose Biosciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Ly","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Basyal","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Rice","sequence":"additional","affiliation":[{"name":"Aptose Biosciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland DG","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342.","journal-title":"Blood"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/gcc.21975","article-title":"Diversity of the juxtamembrane and TKD1 mutations (exons 13\u201315) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data","volume":"51","author":"Schnittger S","year":"2012","unstructured":"Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13\u201315) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012;51(10):910\u201324.","journal-title":"Genes Chromosomes Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2040620719827310","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short NJ","year":"2019","unstructured":"Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jnci\/djm328","article-title":"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia","volume":"100","author":"Zhang W","year":"2008","unstructured":"Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. JNatlCancer Inst. 2008;100(3):184\u201398.","journal-title":"JNatlCancer Inst"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3324\/haematol.2010.030452","article-title":"Phase I study of sorafenib in patients with refractory or relapsed acute leukemias","volume":"96","author":"Borthakur G","year":"2011","unstructured":"Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62\u20138.","journal-title":"Haematologica"},{"issue":"9","key":"ref6","first-page":"2363","article-title":"Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies","volume":"20","author":"Zhang W","year":"2014","unstructured":"Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, et al. Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. ClinCancer Res. 2014;20(9):2363\u201374.","journal-title":"ClinCancer Res"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith CC","year":"2014","unstructured":"Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014;111(14):5319\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl AE","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol. 2017;18(8):1061\u201375.","journal-title":"Lancet Oncol"},{"issue":"29","key":"ref9","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status","volume":"31","author":"Cortes JE","year":"2013","unstructured":"Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith CC","year":"2015","unstructured":"Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29(12):2390\u20132.","journal-title":"Leukemia"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith CC","year":"2017","unstructured":"Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130(1):48\u201358.","journal-title":"Blood"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","article-title":"The Dual MEK\/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations","volume":"76","author":"Zhang W","year":"2016","unstructured":"Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, et al. The Dual MEK\/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Res. 2016;76(6):1528\u201337.","journal-title":"Cancer Res"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/sj.leu.2402317","article-title":"Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts","volume":"15","author":"Birkenkamp KU","year":"2001","unstructured":"Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001;15(12):1923\u201331.","journal-title":"Leukemia"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1947601911416357","article-title":"Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2","volume":"2","author":"Salvatori B","year":"2011","unstructured":"Salvatori B, Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S, Messina M, et al. Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer. 2011;2(5):585\u201392.","journal-title":"Genes Cancer"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2013-06-511154","article-title":"Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia","volume":"123","author":"Rushworth SA","year":"2014","unstructured":"Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229\u201338.","journal-title":"Blood"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc904","article-title":"c-MYC: more than just a matter of life and death","volume":"2","author":"Pelengaris S","year":"2002","unstructured":"Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2(10):764\u201376.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood-2014-06-585216","article-title":"FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation","volume":"125","author":"Oellerich T","year":"2015","unstructured":"Oellerich T, Mohr S, Corso J, Beck J, Dobele C, Braun H, et al. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. Blood. 2015;125(12):1936\u201347.","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"12949","DOI":"10.1038\/srep12949","article-title":"Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia","volume":"5","author":"Pillinger G","year":"2015","unstructured":"Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, et al. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. Sci Rep. 2015;5:12949.","journal-title":"Sci Rep"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/kjh.2012.47.3.178","article-title":"Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells","volume":"47","author":"Kim SJ","year":"2012","unstructured":"Kim SJ, Jang JE, Cheong JW, Eom JI, Jeung HK, Kim Y, et al. Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. Korean J Hematol. 2012;47(3):178\u201385.","journal-title":"Korean J Hematol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.leukres.2010.07.034","article-title":"High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia","volume":"35","author":"Lucena-Araujo AR","year":"2011","unstructured":"Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res. 2011;35(2):260\u20134.","journal-title":"Leuk Res"},{"issue":"11","key":"ref21","first-page":"2706","article-title":"CD34(+)\/CD38(-) acute myelogenous leukemia cells aberrantly express Aurora kinase A","volume":"133","author":"Yang J","year":"2013","unstructured":"Yang J, Ikezoe T, Nishioka C, Nobumoto A, Udaka K, Yokoyama A. CD34(+)\/CD38(-) acute myelogenous leukemia cells aberrantly express Aurora kinase A. Int J Cancer. 2013;133(11):2706\u201319.","journal-title":"Int J Cancer"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson B","year":"2015","unstructured":"Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2015;34(5):537\u201345.","journal-title":"Oncogene"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-015-2766-z","article-title":"Direct and indirect targeting of MYC to treat acute myeloid leukemia","volume":"76","author":"Brondfield S","year":"2015","unstructured":"Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, et al. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015;76(1):35\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2014.07.108","article-title":"Novel acylureidoindolin-2-one derivatives as dual Aurora B\/FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"85","author":"Jagtap AD","year":"2014","unstructured":"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, et al. Novel acylureidoindolin-2-one derivatives as dual Aurora B\/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem. 2014;85:268\u201388.","journal-title":"Eur J Med Chem"},{"year":"2021","author":"Tariq MU","unstructured":"Tariq MU, Furqan M, Parveen H, Ullah R, Muddassar M, Saleem RSZ et al. CCT245718, a dual FLT3\/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.Br J Cancer. 2021.","key":"ref25"},{"year":"2021","author":"Joshi SK","unstructured":"Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer Cell. 2021.","key":"ref26"},{"year":"2022","author":"Rice WG","unstructured":"Rice WG, Howell SB, Zhang H, Rastgoo N, Local A, Kurtz SE et al. Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia.Molecular cancer therapeutics. 2022.","key":"ref27"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1097-0320(20000501)40:1<19::AID-CYTO3>3.0.CO;2-3","article-title":"Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes","volume":"40","author":"Clodi K","year":"2000","unstructured":"Clodi K, Kliche K-O, Zhao S, Weidner D, Schenk T, Consoli U, et al. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes. Cytometry. 2000;40(1):19\u201325.","journal-title":"Cytometry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan E","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"issue":"7397","key":"ref30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith CC","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260\u20133.","journal-title":"Nature"},{"year":"2019","author":"Garcia-Gutierrez L","unstructured":"Garcia-Gutierrez L, Delgado MD, Leon J. MYC Oncogene Contributions to Release of Cell Cycle Brakes.Genes (Basel). 2019;10(3).","key":"ref31"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1535-7163.MCT-08-0754","article-title":"The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model","volume":"8","author":"VanderPorten EC","year":"2009","unstructured":"VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009;8(4):930\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter BZ","year":"2022","unstructured":"Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107(1):58\u201376.","journal-title":"Haematologica"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.tranon.2022.101354","article-title":"Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD\/D835 mutant AML","volume":"18","author":"Yamatani K","year":"2022","unstructured":"Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, et al. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD\/D835 mutant AML. Transl Oncol. 2022;18:101354.","journal-title":"Transl Oncol"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD + acute myeloid leukemia models","volume":"106","author":"Singh Mali R","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD + acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346.","journal-title":"Haematologica"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/17474086.2017.1397510","article-title":"Midostaurin\/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia","volume":"10","author":"Luskin MR","year":"2017","unstructured":"Luskin MR, DeAngelo DJ. Midostaurin\/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol. 2017;10(12):1033\u201345.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"ref37","first-page":"1965","article-title":"Acute myeloid leukemia (AML) can be oligoclonal","volume":"7","author":"Schmetzer HM","year":"1993","unstructured":"Schmetzer HM, Gerhartz HH. Acute myeloid leukemia (AML) can be oligoclonal. Leukemia. 1993;7(12):1965\u201370.","journal-title":"Leukemia"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2020.11.011","article-title":"Dissecting Clonal Heterogeneity in AML","volume":"38","author":"Schuringa JJ","year":"2020","unstructured":"Schuringa JJ, Bonifer C. Dissecting Clonal Heterogeneity in AML. Cancer Cell. 2020;38(6):782\u20134.","journal-title":"Cancer Cell"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.onc.1201520","article-title":"Regulation of c-myc expression by Ras\/Raf signalling","volume":"16","author":"Kerkhoff E","year":"1998","unstructured":"Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR. Regulation of c-myc expression by Ras\/Raf signalling. Oncogene. 1998;16(2):211\u20136.","journal-title":"Oncogene"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bcp.2013.10.022","article-title":"AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia","volume":"87","author":"Eriksson A","year":"2014","unstructured":"Eriksson A, Kalushkova A, Jarvius M, Hilhorst R, Rickardson L, Kultima HG, et al. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochem Pharmacol. 2014;87(2):284\u201391.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers RM","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384.","journal-title":"Nat Genet"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.onc.1208273","article-title":"Polo-like kinases and oncogenesis","volume":"24","author":"Eckerdt F","year":"2005","unstructured":"Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene. 2005;24(2):267\u201376.","journal-title":"Oncogene"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0955-0674(98)80121-X","article-title":"Polo-like kinases: positive regulators of cell division from start to finish","volume":"10","author":"Nigg EA","year":"1998","unstructured":"Nigg EA. Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol. 1998;10(6):776\u201383.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"ref44","first-page":"121","article-title":"Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors","volume":"20","author":"Dai W","year":"2002","unstructured":"Dai W, Liu T, Wang Q, Rao CV, Reddy BS. Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int J Oncol. 2002;20(1):121\u20136.","journal-title":"Int J Oncol"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1083\/jcb.200403084","article-title":"Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2","volume":"166","author":"Gruneberg U","year":"2004","unstructured":"Gruneberg U, Neef R, Honda R, Nigg EA, Barr FA. Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J Cell Biol. 2004;166(2):167\u201372.","journal-title":"J Cell Biol"},{"issue":"14","key":"ref46","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.4161\/cc.29267","article-title":"Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia","volume":"13","author":"Sparta AM","year":"2014","unstructured":"Sparta AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, et al. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle. 2014;13(14):2237\u201347.","journal-title":"Cell Cycle"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2404593","article-title":"Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines","volume":"21","author":"Furukawa Y","year":"2007","unstructured":"Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia. 2007;21(5):1005\u201314.","journal-title":"Leukemia"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-015-0150-2","article-title":"Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family","volume":"22","author":"Kawai M","year":"2015","unstructured":"Kawai M, Nakashima A, Kamada S, Kikkawa U. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family. J Biomed Sci. 2015;22:48.","journal-title":"J Biomed Sci"},{"issue":"38","key":"ref49","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","article-title":"Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy","volume":"57","author":"Manley PW","year":"2018","unstructured":"Manley PW, Caravatti G, Furet P, Roesel J, Tran P, Wagner T, et al. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. Biochemistry. 2018;57(38):5576\u201390.","journal-title":"Biochemistry"},{"year":"2022","author":"Zhang W","unstructured":"Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B et al. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through inhibition of autophagy.Haematologica. 2022.","key":"ref50"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra VA","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):145\u201353.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti A","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11(2):25.","journal-title":"Blood Cancer J"},{"issue":"9","key":"ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose P","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva M","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375\u201388.","journal-title":"Cancer Cell"},{"issue":"8","key":"ref55","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon CM","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019;9(8):1050\u201363.","journal-title":"Cancer Discov"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang Q","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"ref57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.leu.2404477","article-title":"The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells","volume":"21","author":"Cate B","year":"2007","unstructured":"ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia. 2007;21(2):248\u201352.","journal-title":"Leukemia"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2570204\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2570204\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:02:00Z","timestamp":1719000120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2570204\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":57,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2570204\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1080\/10428194.2024.2364839","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,2,22]]},"subtype":"preprint"}}